|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In malignant FNABs, BRAF(V600E) mutation was significantly associated with presence of extra-thyroidal extension and metastases after surgery.
|
21948220 |
2011 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additional analyses of multiple metastatic samples from individual patients using the highly sensitive MS-PCR without microdissection revealed that 5/19 (26%) patients had metastases that were discordant for the BRAF(V600E) mutation.
|
22235286 |
2012 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
At univariate analysis the worst outcome for PTC patients was significantly correlated with clinicopathological features (i.e. age, tumor size, extrathyroid extension, lymph node and distant metastases, advanced stage, vascular endothelial growth factor expression, and vascular invasion) and the BRAF(V600E) mutation (P < 0.002).
|
18682506 |
2008 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with extrathyroidal invasion (P < 0.0001), multicentricity (P = 0.0026), presence of nodal metastases (P = 0.0009), class III vs. classes I and II (P < 0.00000006), and absence of tumor capsule (P < 0.0001), in particular in follicular- and micro-PTC variants.
|
17785355 |
2007 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
|
22105775 |
2012 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E gene mutation was documented in this lesion, and the patient received vemurafenib, with dramatic improvement noted on positron emission tomography scan after 2 months of treatment, soon followed by development of extensive metastases, including to brain.
|
23715079 |
2013 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
|
24888229 |
2014 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E was associated with advanced TNM (P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2, P = 0.004) in colon cancer patients.
|
25367198 |
2014 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation was identified in 1% of patients only. p53 protein was lowly expressed in TGCT metastases compared to the matched primary tumors.
|
27085458 |
2016 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
|
27203149 |
2017 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutations were commonly identified in right-sided tumors and showed a high incidence of peritoneal and distant lymph nodes metastases.
|
29037218 |
2017 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation testing of colorectal tumors demonstrating aberrant MLH1 protein expression by IHC was the most common secondary tumor test, with 53% of laboratories performing the test; 15% of laboratories also applied the BRAF V600E test to endometrial tumors with aberrant MLH1 expression despite no evidence for its utility.
|
30294856 |
2018 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V599E) tended to be associated, although not significantly, with a greater volume and extension of the tumour and with lymph-nodal metastases at surgery.
|
15272920 |
2004 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation is identified in a subset of cutaneous metastases from PTC.
|
17387744 |
2007 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) was characterized in 113 PTC patients diagnosed with pT1aNo-x (one PTC focus with a diameter <1 cm, without lymph node or distant metastases according to IUCC/AJCC TNM staging system 2010).
|
24354346 |
2014 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinically, patients with V600K tumors experience distant metastases sooner and have an increased risk of relapse and shorter survival than patients with V600E tumors.
|
28858076 |
2017 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
|
29119584 |
2018 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Extended BRAF testing using PCR for 9 mutations and VE1 immunohistochemistry for BRAF V600E detection on 95 lesions including 40 primary melanomas with their matched metastases (n = 42), recurrences (n = 9) and second primaries (n = 4) was performed.Nine patients had multiple metastases.
|
25236573 |
2014 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In line with the previous reports, NRAS/BRAF mutations were rare; only one metastatic tumor had an NRAS E61R mutation, and one primary tumor and two metastases harbored BRAF V599E mutations.
|
16098043 |
2005 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, this study provides a mechanistic basis for targeting Mek and not B-Raf in the mutant (V600E)B-Raf signaling cascade to inhibit melanoma metastases.
|
16912199 |
2006 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the context of metastatic PTC with SCC dedifferentiation, the presence of the identical BRAF (V600E) (c.1799 T > A) mutation in both components might help rule out tumor to tumor metastasis.
|
26521063 |
2016 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, the occurrence and percentage of the BRAF V600E mutated allele was not preferentially associated with the development of metastases and the average mutated allele percentage decreased as the tumor progresses from the primary site to the lymph node metastatic sites.
|
23533235 |
2013 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, by droplet digital PCR, the V600E mutation was also detected in the first primary, and the V600K in the second primary and metastases.
|
30222690 |
2019 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, cells carrying the BRAF(V600E) mutation were not only found among cells surrounding the primary tumor but were also present in the stroma of melanoma metastases as well as in a histologically tumor-free re-excision sample from a patient who subsequently developed a local recurrence.
|
27338362 |
2016 |
|
Secondary Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutant allele-specific imbalance of the p.V600E mutation was predominantly present in specimens with distant organ metastases (79% versus 27% in LN metastases versus 13% in primary cutaneous tumors or adjacent soft tissue, P < .001). p.V600K was detected in 23% of men older than 60 years old, compared with 6% in women older than 60 years old and 2% in both men and women younger than 60 years old (P < .001).
|
25456393 |
2015 |